ASX · COO.AX
Corum Group Limited
A$0.04+A$0.00 (+2.33%)
Corum Group Limited’s quoted price sits in the upper half of its reported 52-week range, 10.2% below the high.
Loading market information…
ASX · LBT.AX · AUD
Stock price, earnings
Quote as of Nov 26, 2024, 05:10 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow LBT Innovations Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
LBT Innovations Limited is dedicated to conceiving, advancing, and bringing to market cutting-edge technological solutions for the healthcare and laboratory sectors. The company's operations span various international locations, including Australia, Switzerland, the United States, the United Kingdom, and Germany. Its offerings include MicroStreak, an automated system designed for streaking and inoculating culture plates, and the Automated Plate Assessment System (APAS), a foundational technology that streamlines the screening and interpretation of culture plates. The firm is also actively developing several other innovations: Automated Gram Strain Assessment, intended for the automated interpretation of gram stain image analysis; WoundVue, an AI-powered tool assisting clinicians with the evaluation and care of chronic wounds; Automated Plate Assessment System Pharma, which leverages sophisticated artificial intelligence image analysis algorithms to automatically identify microbial growth in environmental monitoring applications; and specialized devices capable of detecting biofilms within mammalian tissue. Established in 2004, LBT Innovations Limited maintains its headquarters in Adelaide, Australia.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$0.04+A$0.00 (+2.33%)
Corum Group Limited’s quoted price sits in the upper half of its reported 52-week range, 10.2% below the high.
A$0.02+A$0.00 (+7.14%)
Living Cell Technologies Limited’s quoted price sits in the upper half of its reported 52-week range, 16.67% below the high.
A$0.01A$0.00 (0.0%)
Creso Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 83.02% below the high.
$8.72+$0.39 (+4.68%)
Kazia Therapeutics Ltd ADR’s quoted price sits in the lower half of its reported 52-week range, 49.89% below the high.
A$0.04A$0.00 (0.0%)
CardieX Limited’s quoted price sits in the lower half of its reported 52-week range, 79.43% below the high.
A$0.42+A$0.01 (+2.44%)
MGC Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 96.18% below the high.
A$0.04-A$0.00 (-6.98%)
Rhinomed Limited’s quoted price sits in the lower half of its reported 52-week range, 60.0% below the high.
A$0.02A$0.00 (0.0%)
Oventus Medical Limited’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
